TURMETABART ADIZUTECAN
UNII U9G63L4FA6

Substance Identification & Data

This profile provides standardized clinical and technical data for Turmetabart Adizutecan, uniquely identified by the FDA Unique Ingredient Identifier (UNII) U9G63L4FA6.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3034205-72-3 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

U9G63L4FA6

CAS Registry Number

3034205-72-3

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

TURMETABART ADIZUTECAN

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C198215

National Cancer Institute reference terminology for clinical and research data.

INN ID

13671

Sequential identifier assigned via the WHO International Nonproprietary Name program.

Substance Type

Turmetabart Adizutecan

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Turmetabart Adizutecan. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Turmetabart Adizutecan

Common Names & Synonyms

H-gamma1 heavy chain humanized (1-444) [VH (Homo sapiens IGHV5-51*01 (88.3%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.8] (26-33.51-58.97-104)) (1-115) -Homo sapiens IGHG1*01, G1m17,1 CH1 K120, CH3 D12, L14, 15-G1v37 h S5 (CH1 K120(212) (116-213), hinge 1-15 C5>S (218) (214-228), CH2 (229-338), CH3 D12 (354), L14 (356) (339-443), CHS K2>del (444)) (116-444)], with L-kappa light chain humanized (1'-218') [V-KAPPA (Homo sapiens IGKV3D-11*02 (87.2%) -IGKJ4*01 (100%), CDR-IMGT [10.3.9] (27'-36'.54'-56'.93'-101')) (1'-111') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (157'), V101 (195')) (112'-218')]; dimer (224-224'': 227-227'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa; substituted at the sulfur atoms of the six L-cysteinyl residues 234, 237, 218', 234'', 237'' and 218''' with 2-{[(2S)-1-{[(2S)-1-({3-[(7S)-7-ethyl-7-hydroxy-8,11-dioxo-7,8,11,13-tetrahydro-2H,10H-[1,3]dioxolo[4,5-g]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-14-yl]bicyclo[1.1.1]pentan-1-yl}amino)-1-oxopropan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-2-oxoethyl (adizutecan)

Immunoglobulin G1 [218-serine,de-445-lysine], anti-(human seizure protein 6 homolog) (human-Mus musculus monoclonal PR-1744211 γ1-chain), complex with human-Mus musculus monoclonal PR-1744211 κ-chain, dimer, 218′′,218′′′,224,224′,227,227′-hexakis(thioether) with N-(2-mercaptoacetyl)-L-valyl-N-[3-[(7S)-7-ethyl-7,8,11,13-tetrahydro-7-hydroxy-8,11-dioxo-10H-1,3-dioxolo[4,5-g]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-14-yl]bicyclo[1.1.1]pent-1-yl]-L-alaninamide

immunoglobulin G1-kappa, anti-[Homo sapiens SEZ6 (seizure related 6 homolog)], humanized monoclonal antibody, conjugated on six cysteinyl residues to adizutecan, comprising a linker and a camptothecin derivative (turmetabart adizutecan)

turmetabart adizutecan [INN]

External Clinical & Regulatory Resources

Previous UNIIU9G216FF6S

Next UNIIU9G6UFV40X